Nature of change: Appointment of Chief Executive Officer (CEO)
Name and details: Mr. Deepak Sapra (no DIN provided in disclosure)
Effective date: November 16, 2026 (appointment approved by Board on August 14, 2026)
Profile and qualifications: Seasoned business leader with 27 years of executive experience, including over 23 years in the pharmaceutical industry. Currently serves as Chief Executive Officer - API and Services at Dr. Reddy's Laboratories Limited (DRL) and as a Board Member of Aurigene Pharma Services.
Current responsibilities: Responsible for global portfolio strategy and leads an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health, and global patient access, with operations across key markets including United States, European Union, Japan, Brazil, China, Mexico, Middle East, Africa, and emerging markets.
Previous experience: Prior roles include Chief Executive Officer - Custom Pharmaceutical Services (leading global CDMO business), Vice President - Global Generics Business Development (2011-2015), and Senior Director - Global Generics Portfolio Management at Dr. Reddy's Laboratories.
Education: Bachelor's degree in Mechanical Engineering from Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur; Master's degree in Management from Indian Institute of Management, Bangalore; Chevening Scholarship recipient at University of Bradford, UK; Fulbright Fellow at Carnegie Mellon University, Pittsburgh, USA.
Relationships: Disclosure states "Not Applicable" for relationships between directors
Regulatory compliance: Appointment made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
Previous KMP: The disclosure does not mention the previous CEO or nature of their exit
Key Financial or Operational Approvals
No financial results, fundraising, or operational approvals mentioned in this disclosure
Strategic or Business Context
No specific business outlook, risk commentary, or strategic initiatives disclosed beyond the CEO appointment
Any Other Material Information
Company details: Gland Pharma Limited, Registered Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Compliance officer: Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer
Regulatory references: Compliance with BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE Circular ref. no. NSE/CML/2018/24, both dated June 20, 2018 (stated as "Not Applicable" for this appointment)
